GSK PLANS $250 MILLION EQUITY INVESTMENT IN VIR BIOTECHNOLOGY

Highlights

• GSK and Vir Biotechnology will focus on making drugs and vaccines against COVID-19

• Vir Biotechnology will continue it’s partnership with other companies

• Shares of Vir Biotechnology rose by 30 percent on the Nasdaq

Pharma giant GlaxoSmithKline based out of London, has decided to make an equity investment worth $250 million in a small biotechnology company which is bas....